Last reviewed · How we verify

NCT03384771: Prompt-F

Predictors of Outcomes in MBSR Participants From Teacher Factors

Completed Last updated 3 July 2024
What this trial tests

trial testing MBSR in Healthy in 219 participants. Completed in 26 January 2020.

Timeline
11 January 2017
Primary endpoint
26 January 2020
26 January 2020

Quick facts

Lead sponsorUniversity of California, San Francisco
StatusCompleted
Study typeOBSERVATIONAL
Enrollment219
Start date11 January 2017
Primary completion26 January 2020
Estimated completion26 January 2020
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of California, San Francisco

Who can join

18 and older, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Objectives. The primary objective of the current proposal is to identify teacher-related factors that can be feasibly measured and shown to predict mindfulness-based intervention (MBI) participant outcomes. The secondary objective of this R34 proposal is to lay the groundwork for a large-scale R01-funded study in which the investigators anticipate studying participants in Mindfulness-Based Stress reduction (MBSR) courses provided by 50 or more teachers in a range of university- and community-based settings.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of MBSR

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other University of California, San Francisco trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03384771.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing